Premium
Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance
Author(s) -
Topcu Semra,
Tok Derya,
Caliskan Mustafa,
Ozcimen Emel Ebru,
Gullu Hakan,
Uckuyu Ayla,
Erdogan Dogan,
Zeyneloglu Hulusi,
Muderrisoglu Haldun
Publication year - 2006
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2006.02551.x
Subject(s) - metformin , medicine , polycystic ovary , insulin resistance , coronary flow reserve , endocrinology , cardiology , diabetes mellitus , insulin , coronary artery disease
Summary Background Women with polycystic ovary syndrome (PCOS) are thought to have increased cardiovascular risk. Metformin therapy reduces whole‐body insulin resistance (IR) in patients with type‐2 diabetes mellitus (DM). Objective As insulin resistance accompanying PCOS may be reversed by metformin therapy, we hypothesized that metformin therapy might improve coronary microvascular functions in women with PCOS and IR. Patients and methods We treated 16 women with PCOS and IR with metformin, and measured coronary flow reserve (CFR) at the beginning and after 6 months of metformin therapy using transthoracic second‐harmonic Doppler echocardiography. Results At the end of the 6 months of metformin therapy, baseline coronary diastolic peak flow velocity (DPFV) did not change significantly (from 24·6 ± 4·3 to 23·0 ± 3·1, P = 0·106); however, hyperaemic coronary DPFV (from 68·2 ± 12·7 to 74·5 ± 9·7, P = 0·08), and CFR (from 2·75 ± 0·48 to 3·3 ± 0·5, P = 0·016) was significantly improved by metformin therapy. Conclusion In women with PCOS, coronary microvascular function and CFR are significantly improved by 6 months of therapy with metformin.